Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients

Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients: A Retrospective, Case-control Study

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04434118

Enrollment

Registered

2020-06-16

Start date

2020-03-20

Completion date

2021-12-30

Last updated

2022-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID, Rheumatoid Arthritis

Brief summary

Rheumatoid arthritis (RA) patients have an underlying immune deficiency and typically treated with immunosuppressive drugs, which may increase the risk of COVID-19 infection. Hydroxychloroquine (HCQ) has been found to possess antiviral activity against COVID-19. Thus, the aim of this study to investigate the ability of HCQ to reduce the risk of COVID-19 among RA patients.

Interventions

DRUGTraditional antirheumatic drugs

Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

\- Data of all definite cases of RA were collected and reviewed from complete medical records of patients by a team that included 2 trained physicians using a pretested data collection form.

Exclusion criteria

* The

Design outcomes

Primary

Measure	Time frame	Description
The risk of COVID-19 infection among RA patients	12 week	Realtion between hydroxychloroquine use and COVID-19 infection

Secondary

Measure	Time frame	Description
The incidence of hospitalization for Covid-19 patients.	12 week	Number of cases and number of hospitalization days

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026